As the year winds down, good riddance might be a popular sentiment for specialty pharma, which underperformed against the S&P 500 for the first time since 2009 as Martin Shkreli, Epipen "gauging" and Valeant "scandal" stories took their toll. But the theme for 2017 might not be a whole lot better. Try uncertainty.
Also see
Livermore Partners Huge Gain On Valeant (VRX) Short
Steamboat Capital Valeant Short Offset
Even though Morgan Stanley is calling execution key to the industry’s prospects in the new year, it is...
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!This article is only available for Premium Members
Subscribe today and get :
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually
